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Dear Editor,
An 83-year-old woman developed yellow-brown-
ish infiltrates, nodules, and tumors mimicking xantho-
mas, mostly involving the periorbital and chest area 
within three months (Figure 1). She had no abnor-
malities in serum cholesterol or triglycerides levels. 
A detailed laboratory analysis revealed the presence 
of mild monoclonal gammopathy with a presence of 
immunoglobulin G (IgG) kappa light chains; however, 
according to hematologist consultation, it did not 
require medical intervention. Imaging assessment 
and ultrasound examination did not show any spe-
cific involvement of internal organs. The skin biopsy 
demonstrated necrobiotic areas alternated with foci 
of xanthogranulomatous infiltration throughout the 
reticular dermis with extension into subcutaneous 
tissue. The granulomatous infiltrate was composed 
of epithelioid, foamy histiocytes in addition to con-
spicuous giant cells of the Touton type and foreign 
body type, as well as variable numbers of lympho-
cytes, plasma cells, and neutrophiles. Lipid vacuoles 
were seen within the foci of necrobiosis and xantho-
granulomatous infiltration (Figure 2). Two months af-
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ter first admission to our department, the first signs of 
necrosis within the lesions were noted, and massive 
necrosis of skin lesions occurred after the following 5 
months (Figure 1). 
Based on the clinical manifestation and histologi-
cal and laboratory findings, the diagnosis of necrobi-
otic xanthogranuloma (NXG) was established. In our 
patient, the extremely late onset of the disease, its 
very aggressive course, and the absence of malignant 
hematological disorder were remarkable. The general 
condition improved after local treatment and a low 
dose of prednisone. however, patient anamnesis re-
vealed myocardial infarction in the past, congestive 
heart failure, and atrial fibrillation. Eventually, the 
patient died due to acute heart failure before alkyl-
ating agents could be administered; we consider the 
patient’s death to have been unrelated to NXG. 
NXG is a rare, chronic granulomatous disorder 
which was first described in 1980 by Kossard and 
Winkelmann (1). Currently, less than one hundred fif-
ty cases of this syndrome have been reported in the 
Figure 1. Skin changes by the first (a1, a2), second (b1, b2), and third hospitalization (c1, c2).
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literature worldwide (2,3). The disease occurs during 
adulthood, slightly more frequently in women, and 
usually after the age of 60 years, although the young-
est reported patient was 17 years old (3). 
The disease initially manifests as xanthoma-like 
eruptions of yellowish or red-orange papules and 
nodules that coalesce into indurated plaques (4). The 
size of the lesions typically increases over time or with 
the next recurrences. In comparison to hyperlipemic 
and normolipemic xanthomas, the lesions are firmer, 
more prominent, and more polymorphic (3) with su-
perficial telangiectasias, sometimes erythematous 
and/or violaceous borders, and atrophy (5). Ulcer-
ations of the lesions were observed in about 50% of 
patients and tended to be extensive and progressive 
(4). Skin lesions of NXG can occur anywhere on the 
body. however, about two-thirds of patients had peri-
orbital involvement, particularly on the upper and/or 
lower eyelids or elsewhere on the face. The second 
most commonly affected site was the trunk, predomi-
nantly the chest (3-6). however, many skin lesions first 
appear on the trunk or extremities and subsequently 
involve the periorbital area (4). More than one body 
area was affected in about 90% of the published cases 
(3,4). In individual cases, the occurrence of NXG was 
noted within scars, after trauma, or in a previously X-
ray irradiated area (5). Lesions may be asymptomatic; 
however, over half of patients asked reported various 
symptoms, predominantly itching but also burning, 
tenderness, and even pain (4,5). 
Periorbital skin lesions are often accompanied 
by ophthalmic manifestations, mainly scleritis, cho-
roiditis, or conjunctivitis (3), and with complications 
such as blepharoptosis, restricted ocular motility, 
and proptosis (4,5). Extracutaneous lesions are most 
commonly seen in the respiratory tract, including the 
lungs and larynx, followed by the myocardium, oral 
cavity, skeletal muscles, kidneys, ovaries, intestine, 
and other sites (5,6). Extracutaneous involvement 
was reported in less than 20% of cases (3), but its fre-
quency seems to have increased in recent years (5).
regarding laboratory abnormalities, the majority 
of patients with NXG (70% and up to 90% depending 
on the studied population) have a monoclonal gam-
mopathy (more often IgG-kappa than IgG-lambda). 
Elevated erythrocyte sedimentation rate, anemia, leu-
kopenia, low C1 and C4 levels, and cryoglobulinemia 
are also frequently present (3-6). Incisional biopsy is 
recommended to confirm the diagnosis of NXG, but 
correlations between the clinical presentation and 
specific histopathologic findings have been poorly 
characterized so far. The histopathology shows an 
inflammatory infiltrate composed of macrophages, 
foam cells, plasma cells, and other inflammatory cells 
as well as Touton and foreign body-type giant cells 
in the dermis and subcutaneous tissue. Necrobiosis 
is usually present, and nodular lymphoid aggregates 
are common. Cholesterol clefts or asteroid bodies 
are rare or absent. The epidermis may be atrophic or 
normal. Special stains are not helpful in establishing 
the diagnosis of NXG, but immunohistochemistry for 
CD68 is positive while it is always for CD1a and PS100 
negative, like in non-X histiocytosis (4,5). In patients 
without a known myeloproliferative disorder, bone 
marrow biopsy may reveal atypical or increased plas-
ma cells and, very rarely, true multiple myeloma (5).
As mentioned above, NXG can be a manifestation 
of multiple myeloma. however, chronic lymphocyte 
leukemia, B-cell lymphoma, and other lymphoprolif-
erative diseases have also been reported in patients 
with NXG (3). remarkably, hematological disorders 
may emerge many years before or after the onset of 
skin lesions (even up to 11 years) (4).
According to available literature data, the course of 
the disease is usually chronic and slowly progressive, 
and the prognosis is relatively good in the absence of 
co-occurrence of malignant hematological disorders 
([5-7). Aside from hyperlipemic and normolipemic 
xanthomas, the differential diagnosis of NXG includes 
multifocal necrobiosis lipoidica, granuloma annulare, 
foreign-body granuloma, juvenile xanthogranuloma, 
rheumatoid nodules, and amyloidosis (4). In 5 cases 
from the literature, xanthoma and NXG were present 
at the same time (3).
Despite several hypotheses, the etiopathogenesis 
of NXG remains unknown (3,4,8). For that reason and 
due to the rarity of the disease, the optimal therapy 
has not been not defined. Frequently, chlorambucil or 
melphalan have been used alone or in combination 
with prednisone (4). Treatment may result in remis-
sion of symptoms on the skin, but it does not provide 
Figure 2. hematoxylin-eosin stained skin biopsy speci-
men, magnification: ×100 (a, survey) and ×400 (b, de-
tailed).
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a permanent cure (8). There are also single reports of 
the successful use of thalidomide, lenalidomide, cy-
clophosphamide, dexamethasone, interferon 2a and 
2b, plasmapheresis and hydroxychloroquine, azathio-
prine, infliximab, and autologous bone marrow trans-
plantation (3). Methotrexate seems to be ineffective 
(9). Local therapy, including local steroids, laser Co2, 
or radiotherapy, results in partial improvement (3,4). 
Skin lesions which relapsed or were unresponsive to 
treatment could be excised surgically and the defects 
resurfaced with skin grafts. [2]. 
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